However, a recent phase III trial found that pembrolizumab should not be used in combination with pemetrexed and platinum chemotherapy in EGFR‐mutant metastatic NSCLC who have progressed on first‐line tyrosine kinase inhibitor therapy, as it did not provide OS and PFS benefits compared with chemotherapy alone [91]. Here, EGFR is linked to non-small cell lung carcinoma.